Nurix Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nurix Therapeutics (NRIX).

Price Target Range — 11 Quarters

Analyst Consensus — 19 Analysts

18Buy

1Hold

Consensus RatingOutperform# Analysts19Avg. Consensus PT$33Upside to Avg. PT+30.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$34→$36
Oct 13, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$36→$35
Oct 13, 2026	Oppenheimer	Kostas Biliouris	PT Raise	Outperform	$28→$32
Oct 13, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$34→$33
Oct 13, 2026	Baird	Joel Beatty	PT Raise	Outperform	$33→$36
Oct 13, 2026	Needham	Gil Blum	Maintained	Buy	$34
Aug 10, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$33→$36
Aug 4, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jul 28, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$36→$38
Jul 22, 2026	UBS	David Dai	PT Raise	Buy	$23→$31
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$30→$34
Jul 10, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$32→$34
Jul 10, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$30→$33
Jul 10, 2026	Stifel	Stephen Willey	PT Raise	Buy	$34→$40
Jul 10, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$32
Jul 10, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jul 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$32→$34
Jun 18, 2026	Baird	Joel Beatty	PT Raise	Outperform	$26→$33
Jun 15, 2026	Needham	Gil Blum	Maintained	Buy	$34
Jun 10, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$32

More with Benzinga EdgeGet Access

Analyst Ratings News

SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.

Benzinga Newsdesk

Nurix Therapeutics Inc

Nurix Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

PRO
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

PRO
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

People Also Watch

People Also Watch

Nurix Therapeutics Inc

Nurix Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

PRORBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

PROOppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

PROTruist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

PROBaird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

PRO
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

PRO
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

PRO
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

PRO
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36